Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
PSP-corticobasal syndrome (PSP-CBS) is an atypical variant of progressive supranuclear palsy (PSP), a rare late-onset neurodegenerative disease.
Biomarker and diagnostic research for progressive supranuclear palsy-corticobasal syndrome has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for progressive supranuclear palsy-corticobasal syndrome.
35 publications have been identified in PubMed for progressive supranuclear palsy-corticobasal syndrome. Research spans Epidemiology / Natural History (31%), Review / Meta-Analysis (29%), and Diagnostic / Biomarker (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 11 | 31% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:32 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
10 |
29% |
Testing and diagnosis research | 6 | 17% |
Patient case studies | 3 | 9% |
Clinical study results | 3 | 9% |
Laboratory research | 2 | 6% |
Rodriguez-Porcel F (2026). [PMID: 41518136](https://pubmed.ncbi.nlm.nih.gov/41518136/). *Mov Disord Clin Pract*. [Review / Meta-Analysis]
Wang AC (2026). [PMID: 41562273](https://pubmed.ncbi.nlm.nih.gov/41562273/). *Mov Disord*. [Basic Science / Preclinical]
Wu LY (2026). [PMID: 41929290](https://pubmed.ncbi.nlm.nih.gov/41929290/). *medRxiv : the preprint server for health sciences*. [Basic Science / Preclinical]
Kukkle PL (2026). [PMID: 40898879](https://pubmed.ncbi.nlm.nih.gov/40898879/). *Movement disorders clinical practice*. [Review / Meta-Analysis]
Schmidt M (2026). [PMID: 41769249](https://pubmed.ncbi.nlm.nih.gov/41769249/). *Clinical parkinsonism & related disorders*. [Clinical Trial Publication]
McFarland NR (2025). [PMID: 40748119](https://pubmed.ncbi.nlm.nih.gov/40748119/). *Continuum (Minneapolis, Minn.)*. [Review / Meta-Analysis]
Ono Y (2025). [PMID: 39843325](https://pubmed.ncbi.nlm.nih.gov/39843325/). *Parkinsonism & related disorders*. [Epidemiology / Natural History]
Angel MJ (2025). [PMID: 40495913](https://pubmed.ncbi.nlm.nih.gov/40495913/). *Clinical parkinsonism & related disorders*. [Diagnostic / Biomarker]
Vaughan DP (2025). [PMID: 40138021](https://pubmed.ncbi.nlm.nih.gov/40138021/). *Journal of neurology*. [Epidemiology / Natural History]
Urso D (2025). [PMID: 40920400](https://pubmed.ncbi.nlm.nih.gov/40920400/). *JAMA neurology*. [Review / Meta-Analysis]
AI-curated news mentioning progressive supranuclear palsy-corticobasal syndrome
Updated Sep 6, 2026
A study published in PubMed examines groaning in patients with progressive supranuclear palsy, providing insights from a large Asian cohort. The findings may enhance understanding of this symptom in the context of the disease.
A scoping review identifies key prognostic factors influencing survival in corticobasal syndrome and corticobasal degeneration. This research provides insights that could guide future studies and clinical approaches.
A study identifies the substantia nigra susceptibility-to-volume ratio derived from quantitative susceptibility mapping (QSM) as a potential biomarker to differentiate progressive supranuclear palsy from Parkinson's disease and multiple system atrophy. This research could enhance diagnostic accuracy for these neurodegenerative disorders.